

## Annual Report 2025



EBMT President

### **Foreword by the EBMT President**

It is with pride and gratitude that I present this foreword to the Annual Report. In 2025, EBMT continued to advance haematopoietic cell transplantation and cellular therapy, improving access, quality, and safety for patients worldwide.

This year has been defined by strategic progress across education, research, clinical excellence, and community engagement. The establishment and rapid development of the **EBMT Education Department** marked a transformative step toward providing more comprehensive and high-quality educational opportunities across professional groups. From the successful EBMT Exam to an extensive series of courses, meetings, and workshops, our commitment to lifelong learning has never been stronger.

The [51st Annual Meeting of the EBMT](#) in Florence brought together more than 6,200 participants from nearly 100 countries, reflecting the Society's expanding global influence and showcasing the vibrant scientific and clinical exchange that defines our community.

In parallel, EBMT Registry developments and research programmes reached important milestones. Achieving ISO/IEC 27001 certification demonstrated our dedication to data security and integrity, while enhancements to the Registry infrastructure and analytical tools have improved usability and quality, empowering centres with stronger real-world evidence.

The publication of updated [\*\*\*Practice Recommendations for HCT and CAR-T Therapy\*\*\*](#) and the [\*\*\*second edition of the EU CAR T-cell Handbook\*\*\*](#) reaffirmed our leadership in harmonising clinical practice and supporting an evolving therapeutic landscape.

A major milestone for HCT and cellular therapy was the release of the [\*\*\*FACT-JACIE 9th Edition HCT Standards and 3rd Edition IEC Standards\*\*\*](#), together with updated manuals. These standards continue to set the global benchmark for quality, patient safety, and excellence in cellular therapy.

A highlight of 2025 has been the welcoming of **new members and centres**, as our global footprint continues to grow and diversify—strengthening our collective expertise and reinforcing the collaborative spirit that lies at the heart of EBMT (see the [membership report](#) for further details).

As EBMT evolves, we have taken important steps to strengthen the organisation for the future. The **Transformation and Consolidation Project**, launched in early 2025, is enhancing our resilience, improving how we operate, and reinforcing the foundations that support our mission—while keeping science at the centre of everything we do. Further progress is planned for 2026.

I encourage you to read the EBMT Annual Report for an overview of our Society's achievements in 2025, including the work of our **Working Parties**, the **Registry**, **educational activities**, the **Nurses Group**, and more.

As my mandate draws to a close, a smooth leadership transition is underway. A structured handover is in place to ensure continuity and sustained delivery in 2026 and beyond. Enhancing career pathways, advancing scientific excellence, improving data quality, and expanding international partnerships will remain central to our work.

To all of you—members, partners, volunteers, educators, researchers, clinicians, and advocates—thank you for your dedication, vision, and unwavering commitment to our shared mission. It is through your contributions that we continue to push boundaries, improve patient care, and shape the future of transplantation and cellular therapy.

Sincerely,

**Anna Sureda**  
EBMT President

[Read more](#) [Read less](#)

[EBMT Annual Report](#)



The EBMT continues to advance excellence in scientific research and education. This commitment is reflected both in our established face-to-face meetings, which remain essential for collaboration and scientific advancement, and in our expanding online educational initiatives, which enhance global accessibility and foster knowledge dissemination across the Haematopoietic Cell Transplantation and Cellular Therapy

community. ... [Read more.](#)

## **Working Parties Activity Reports**

[Acute Leukaemia \(ALWP\)](#)

[Severe Aplastic Anaemia \(SAAWP\)](#)

[Autoimmune Diseases \(ADWP\)](#)

[Chronic Malignancies \(CMWP\)](#)

[Cellular Therapy and Immunobiology \(CTIWP\)](#)

[Inborn Errors \(IEWP\)](#)

[Infectious Diseases \(IDWP\)](#)

[Transplant Complications \(TCWP\)](#)

[Lymphoma \(LWP\)](#)

[Paediatric Diseases \(PDWP\)](#)

[Haemoglobinopathies \(HWP\)](#)

[JACIE](#)

## **More in science**

[EBMT Registry](#)

[Grants](#)

[Publications 2025](#)

EBMT Annual Report

**2025**

## **Education**

# EBMT Education

**Your Education.  
Our Resources.  
One Goal.**

EBMT offers **open-access** platforms, books, and more online educational resources to help you **improve your practice** and offer the best care.



**START A NEW  
LEARNING JOURNEY**

EBMT has established a dedicated Education Department to coordinate and expand its educational activities in alignment with the priorities defined by the Scientific Council. This initiative reinforces EBMT's commitment to continuous professional development, addressing knowledge gaps, promoting best practices, and strengthening international collaboration in HCT and CT. ... [Read more.](#)

## **Educational Resources**

[51st Annual Meeting of the EBMT](#)

[Educational Meetings 2025](#)

[Learning Projects](#)

[EBMT Annual Report](#)





Improving the care of our patients remains a central objective of EBMT. We are committed to empowering, advocating for, and amplifying the voices of patients, survivors, and caregivers worldwide. Throughout the past year, the Nurses Group and the GoCART Coalition have continued to play a vital role in advancing patient-centred care—discover the key activities and achievements that shaped their work in 2025.

## **Patient Care Initiatives**

## Financial Report & Highlights 2025

In 2025, income of EBMT decreased compared to previous years. EBMT’s major sources of income are the Annual Meeting and revenue generated through post-authorisation safety (PAS) studies and pharmaceutical industry-initiated and/or partnered projects. Other sources of income are corporate sponsorships, certification fees, grants and investment income. In particular income through studies was less than previous years and even though income through other activities increased, direct costs related to some of these activities also increased ... [Read more](#)



[See the Financial Report](#)

## Our Society

[Our Mission, Vision & Values](#)

[Membership 2025](#)

[Organisational Structure 2025](#)

[Financial Report & Highlights 2025](#)

[EBMT Partners 2025](#)

[See past Annual Reports](#)

